MedTrace Logo

Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.

NCT03155451 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2017-10-19

No results posted yet for this study

Summary

Epithelial ovarian cancer constitutes one of the most common gynecological malignancies.Because the ovaries lie in the deep pelvic cavity,most ovarian cancer patients are asymptomatic, rendering the majority often diagnosed at an advanced stage.ctDNA in cancer patients often bears similar genetic and epigenetic features to the related tumor DNA.This study aims to detect plasma ctDNA in Diagnosis of Epithelial Ovarian Cancer.

Conditions

  • Epithelial Ovarian Cancer

Interventions

DIAGNOSTIC_TEST

methylation markers screening

ctDNA extraction from plasma samples;bisulfite-treated DNA;DNA methylation levels by deep sequencing-Sequencing; data analysis

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Yu Wang, M.D. · Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-14
Primary Completion
2017-10-18
Completion
2017-10-18

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03155451 on ClinicalTrials.gov